Product Center
Mid-Year Marketing Conference and Promoter Strategic Cooperation Conference Successfully Held
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-07-26
- Views:
(Summary description)From July 20th to July 22nd, 2023, Ab&B Bio-Tech Co., Ltd. JS successfully held the Mid-Year Marketing Conference and Promoter Strategic Cooperation Conference. All members of the company's marketing team and representatives of promotion partners attended this summer event, working together to launch the first year of business for Ab&B Bio-Tech Co., Ltd. JS.
Mid-Year Marketing Conference and Promoter Strategic Cooperation Conference Successfully Held
(Summary description)From July 20th to July 22nd, 2023, Ab&B Bio-Tech Co., Ltd. JS successfully held the Mid-Year Marketing Conference and Promoter Strategic Cooperation Conference. All members of the company's marketing team and representatives of promotion partners attended this summer event, working together to launch the first year of business for Ab&B Bio-Tech Co., Ltd. JS.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-07-26 16:24
- Views:
From July 20th to July 22nd, 2023, Ab&B Bio-Tech Co., Ltd. JS successfully held the Mid-Year Marketing Conference and Promoter Strategic Cooperation Conference. All members of the company's marketing team and representatives of promotion partners attended this summer event, working together to launch the first year of business for Ab&B Bio-Tech Co., Ltd. JS.
At the summary session, Mr. An Youcai, Chairman and General Manager, and Mr. Zhao Guojun, Deputy General Manager, delivered keynote speeches titled "Steady Progress in the First Year of Business" and "Huixin Sets Sail, Dream Pursuit" respectively. They provided practical guidance and shared expectations covering both professional requirements and personal career development. Based on first-half performance and identified challenges, each department presented second-half action plans. Meanwhile, the marketing department conducted targeted business training sessions tailored to the sales team's needs, collaborating to ensure a successful business launch year.
During the Strategic Cooperation Conference, Chairman Mr. An Youcai presented the company's capabilities across talent development, R&D strength, industrial capacity, and partnership strategies, emphasizing integrity and compliance as partnership fundamentals. Deputy General Manager Mr. Zhao Guojun drew historical parallels to propose collaborative principles of unity, mutual benefit, and value co-creation. Promotion partners engaged in lively discussions about current market challenges, sustainable competitive advantages, and premium vaccine branding. Both parties established long-term strategic partnerships.
Additionally, Ab&B Bio-Tech Co., Ltd. JS invited Professor Lin Qian, doctoral supervisor from China University of Political Science and Law, to present a masterclass: "Zeng Guofan's Wisdom: Ancient Strategies for Modern Talent Management". Professor Lin analyzed classical philosophies through contemporary case studies of Huawei and Lenovo, delivering actionable insights on talent identification, utilization, and team leadership. This knowledge-sharing session equipped attendees with actionable management strategies to foster win-win collaborations.
This conference clarified the marketing team's direction, strengthened partner confidence, and reinforced the values of mutual growth and shared success, providing strong momentum for successful product launch and commercialization.

Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us